Walid Kamoun: The Evolution of Survival Rates for Lung Adenocarcinoma Over The Past 20 Years
Walid Kamoun, Vice President, Global Head of R and D Oncology at Servier, shared a post on LinkedIn about recent article by Didier Debieuvre et al., published on NEJM.
“My family and friends often ask me about cancer research and the advancements in oncology. While browsing the latest issues of the New England Journal of Medicine, I came across an insightful paper that highlights the evolution of survival rates for lung adenocarcinoma over the past 20 years outside academic medical centers. The paper nicely illustrates the improved survival with targeted therapies and with immunotherapies increasing 3-year OS rate to more than 35% vs historical 15%.
This is a nice tangible illustration of some of the transformative therapies that emerged over the past 20 years through targeted and immunotherapies. And I am confident that we will continue to advance and improve survival rates for all cancers with unmet medical needs.
Congrats to Dr. Debieuvre and all the KBP-2020 study authors for this great analysis.”
Title: Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020
Authors: Didier Debieuvre, Lionel Falchero, Olivier Molinier, Sébastien Couraud, Alexis Cortot, Nicolas Meyer, Bernard Asselain, Etienne Auvray, Dorine Templement-Grangerat, Acya Bizieux, Jean Tredaniel, Sophie Schneider, Jean-Bernard Auliac, Olivier Bylicki, Alexia Letierce, Hugues Morel
Read The Full Article at NEJM.
More Posts Featuring Lung Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023